Direct evidence that thromboxane mimetic U44069 preferentially constricts the afferent arteriole

Journal of the American Society of Nephrology

Volumn 8, Issue 1, 1997, Pages 25-31

  Hayashi, Koichi ^a   Loutzenhiser, Rodger ^d   Epstein, Murray ^b,c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 9ALPHA,11ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; DILTIAZEM; NIFEDIPINE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ANIMAL TISSUE; ARTERIOLE; ARTICLE; BLOOD VESSEL DIAMETER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ISOLATED KIDNEY; KIDNEY BLOOD FLOW; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASOCONSTRICTION;

EID: 0030699486     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v8125     Document Type: Article

References (46)

1. Welch WJ, Wilcox CS: Potentiation of tubuloglomerular feedback in the rat by thromboxane mimetic: Role of macula densa. J Clin Invest 89: 1857-1865, 1992
2. Bulivant EMA, Wilcox CS, Welch WJ: Intrarenal vasoconstriction during hyperchloremia: Role of thromboxane. Am J Physiol 256: F152-F157, 1989
3. Wilcox CS, Welch WJ: Angiotensin II and thromboxane in the regulation of blood pressure and renal function. Kidney Int 38[Suppl 30]: S81-S83, 1990
4. Wilcox CS, Welch WJ, Snellen H: Thromboxane mediates renal hemodynamic response to infused angiotensin II. Kidney Int 40: 1090-1097, 1991
5. Wilcox CS, Welch WJ: Thromboxane mediation of the pressor response to infused angiotensin II. Am J Hypertens 3: 242-249, 1990
6. 2 by the kidney in glycerol-induced acute renal failure. Prostaglandins 19: 333-347, 1980
7. Lianos E, Andres GA, Dunn MJ: Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis. J Clin Invest 72: 1439-1448, 1983
8. 2 during late nephrotoxic serum glomerulonephritis in the rat. J Clin Invest 85: 1974-1982, 1990
9. 2 production in patients with systemic lupus erythematosus. J Clin Invest 76: 1011-1018, 1985
10. Epstein M, Lifschitz M: Renal eicosanoids as determinants of renal function in liver disease. Hepatology 7: 1359-1367, 1987
11. 2 in the hepatorenal syndrome: Evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 84: 697-703, 1983
12. Laffi G: La Villa G, Pinzani M, Gentilini P: Lipid-derived autacoids and renal function in liver cirrhosis. In: The Kidney in Liver Disease, edited by Epstein M, Philadelphia, Hanley & Belfus, 1996, pp 307-337
13. 2 in renal allograft rejection. Lancet 2: 431-434, 1981
14. Ramos EL, Barri YM, Croker BP, Clapp WL, Peterson JC, Wilcox CS: Thromboxane synthase expression in renal transplant patients with rejection. Transplantation 59: 490-494, 1995
15. Baylis C: Effects of administered thromboxanes on the intact, normal rat kidney. Renal Physiol 10: 110-121, 1987
16. Gerber JG, Ellis E, Hollified J, Nies A: Effect of prostaglandin endoperoxide analogue on canine renal function, hemodynamics and renin release. Eur J Pharmacol 53: 239-246, 1979
17. Loutzenhiser R, Epstein M, Horton C, Sonke P: Reversal of renal and smooth muscle actions of the thromboxane mimetic U-44069 by diltiazem. Am J Physiol 250: F619-F626, 1986
18. Wilkes BM, Solomon J, Maita M, Mento PF: Characterization of glomerular thromboxane receptor sites in the rat. Am J Physiol 256: F1111-F1116, 1989
19. Wilcox CS, Folger WH, Welch WJ: Renal vasoconstriction with U-46619: Role of arachidonate metabolites. J Am Soc Nephrol 5: 1120-1124, 1994
20. Spurney RF, Fan P-Y, Ruiz P, Sanfillippo F, Pisetsky DS, Coffman TM: Thromboxane receptor blockade reduces renal injury in murine lupus nephritis. Kidney Int 41: 973-982, 1992
21. Perico N, Rossini M, Imberti O, Malanchini B, Cornejo RP, Gaspari F, Bertani T, Remuzzi G: Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft. J Am Soc Nephrol 2: 1398-1404, 1992
22. 2 and endoperoxide analogues on cultured rat glomerular mesangial cells. Am J Physiol 251: F1029-F1035, 1986
23. Scharshmidt LA, Lianos E, Dunn MJ: Arachidonate metabolites and the control of glomerular function. Fed Proc 42: 3058-3063, 1983
24. Abe T, Takeuchi K, Takahashi N, Tsutsumi E, Taniyama Y, Abe K: Rat kidney throbomboxane receptor: molecular cloning, signal transduction, and intrarenal expression localization. J Clin Invest 96: 657-664, 1995
25. Hayashi K, Nagahama T, Oka K, Saruta T: Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 19: 31-36, 1996
26. Hayashi K, Epstein M, Loutzenhiser R: Pressure-induced vasoconstriction of renal microvessels in normotensive and hypertensive rats: Studies in the isolated perfused hydronephrotic kidney. Circ Res 65: 1475-1484, 1989
27. Loutzenhiser R, Epstein M, Hayashi K, Horton C: Direct visualization of the effects of endothelin on the renal microvasculature. Am J Physiol 258: F61-F68, 1990
28. Loutzenhiser R, Hayashi K, Epstein M: Calcium antagonists augment glomerular filtration rate (GFR) of angiotensin II-vasoconstricted isolated perfused rat kidneys (IPRK) by dilating afferent but not efferent arterioles [Abstract]. J Cardiovasc Pharmacol 12[Suppl 6]: S149, 1987
29. Loutzenhiser R, Hayashi K, Epstein M: Atrial natriuretic peptide reverses afferent arteriolar vasoconstriction and potentiates efferent arteriolar vasoconstriction in the isolated perfused rat kidney. J Pharmacol Exp Ther 246: 522-528, 1988
30. Steinhausen M, Snoei H, Parekh N, Baker R, Johnson PC: Hydronephrosis: A new method to visualize vas afferens, efferens and glomerular network. Kidney Int 23: 794-806, 1983
31. Epstein M, Flamenbaum W, Loutzenhiser R: Characterization of the renin-angiotensin system in the isolated perfused rat kidney. Renal Physiol 2: 244-256, 1980
32. Dusting G, Moncada S, Vane JR: Vascular actions of arachidonic acid and its metabolites in the perfused mesenteric and femoral beds of the dogs. Eur J Pharmacol 49: 65-72, 1978
33. 2. Stroke 8: 480-483, 1977
34. Loutzenhiser R, Epstein M: Modification of the renal hemodynamic response to vasoconstrictors by calcium antagonists. Am J Nephrol 7[Suppl 1]: 7-16, 1987
35. Welch WJ, Wilcox CS: Modulating role for thromboxane in the tubuloglomerular feedback response in the rat. J Clin Invest 81: 1843-1849, 1988
36. Fleming JT, Parekh N, Steinhausen M: Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am J Physiol 253: F1157-F1163, 1987
37. Carmines PKNavar LG: Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol 256: F1015-F1020, 1989
38. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T: Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 19: 31-36, 1996
39. Saruta T, Kanno Y, Hayashi K, Konishi K: Antihypertensive agents and renal protection: Calcium channel blockers. Kidney Int 49[Suppl 55]: S52-S56, 1996
40. 2+] in renal arterioles. Am J Physiol 265: F677-F685, 1993
41. Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M: Pharmacological actions of SQ29548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 224: 435-441, 1984
42. Takenaka T, Forster H, Epstein M: Protein kinase C and calcium channel activation as determinants of renalvasoconstriction by angiotensin II and endothelin. Circ Res 73: 743-750, 1993
43. Coffman TM, Carr DR, Yarger WE, Klotman PE: Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation 43: 282-285, 1987
44. Pierucci A, Simonetti BM, Pecci G, Mavrikakis G, Feriozzi S, Cinotti GA, Patrgnani P, Ciabattoni G, Patrono C: Improvement of renal function with selective thromboxane antagonism in lupus nephritis. N Engl J Med 320: 421-425, 1989
45. Neumayer H-H, Wagner K: Prevention of delayed graft function in cadaver kidney transplants by diltiazem: Outcoming of two prospective, randomized clinical trials. J Cardiovasc Pharmacol 10[Suppl 10]: S170-S177, 1987
46. Laffi G, Marra F, Carloni V, Azzena G, De Feo ML, Pinzani M, Tosti-Guerva C, Gentilini P: Thromboxane-receptor blockade increases water diuresis in cirrhotic patients with ascites. Gastroenterology 103: 1017-1021, 1992